Business Context and Reporting Period
Company: Nu Skin Enterprises, Inc. (NUS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: Nu Skin develops and distributes premium beauty and wellness products globally through direct selling. The company operates through seven geographic Nu Skin segments and two Rhyz segments (Manufacturing and Rhyz Other).
Key Financial Metrics
| Metric (in thousands, except per share) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $364,211 | $430,145 | $1,114,839 | $1,286,532 |
| Gross Profit | $256,723 | $301,463 | $769,417 | $902,704 |
| Gross Margin % | 70.5% | 70.1% | 69.0% | 70.2% |
| Operating Income | $21,642 | $18,231 | $42,519 | $(98,504) |
| Net Income | $17,079 | $8,302 | $145,713 | $(110,489) |
| Diluted EPS | $0.34 | $0.17 | $2.91 | $(2.23) |
| Cash from Operations (9M) | $63,665 | $85,957 | ||
| Cash & Equivalents (End of Period) | ||||
| Total Debt (Current + Long-term) | $229,044 | $393,613 |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 15% in Q3 and 13% for the nine months ended September 30, 2025, compared to the prior year. This was driven by macroeconomic challenges, reduced consumer spending, and declines in Customers (-10%), Paid Affiliates (-13%), and Sales Leaders (-19%).
- Profitability Improvement: Despite revenue declines, Net Income and EPS improved significantly. Q3 Net Income rose 106% year-over-year. The nine-month period swung from a net loss of $110.5 million in 2024 to a net income of $145.7 million in 2025.
- Debt Reduction: Total debt decreased by approximately $165 million year-over-year, primarily due to a $115 million payment on the term loan facility in January 2025 using proceeds from the sale of the Mavely entity.
- Segment Performance:
- Nu Skin: Revenue declined across most geographic segments, with Mainland China (-19.8%) and South Korea (-22.1%) showing the steepest drops in Q3.
- Rhyz Other: Revenue plummeted 81.4% in Q3 due to the January 2025 sale of the Mavely entity.
Guidance, Outlook, and Management Commentary
- Strategic Priorities: Management is focusing on business model optimization, enhancements to the sales performance plan, and a limited preview of the Prysm iO intelligent wellness platform. No material revenue is expected from Prysm iO in 2025.
- Market Expansion: The company is preparing for a formal launch in India in the second half of 2026, anticipating only nominal revenue from pre-opening activities in Q4 2025.
- Impairments and Restructuring:
- A $25.1 million impairment charge was recorded in Q1 2025 for the BeautyBio asset group due to a strategic shift and reduced revenue forecasts.
- The 2023 restructuring plan charges have been fully incurred; remaining payments are expected in Q4 2025.
- Tax Impact: The effective tax rate for the nine months ended September 30, 2025, was 18.1%, benefiting from $8.1 million in additional R&D credits. The enactment of the "One Big Beautiful Bill Act" (OBBBA) in July 2025 did not have a material impact on the tax provision for the period.
- Capital Allocation: The company repurchased $10.0 million of common stock in the first nine months of 2025. $152.4 million remains available under the repurchase plan. Quarterly dividends of $0.06 per share were maintained.
Investor Verification Checklist
- Mavely Sale Proceeds: Verify the finalization of net working capital adjustments and the total cash/equity received from the Mavely sale ($193.7 million cash + $6.1 million equity interest).
- BeautyBio Strategy: Assess the long-term viability of the BeautyBio brand following the Q1 impairment and the decision to exit certain sales channels.
- China Market Dynamics: Monitor the impact of the relaunched Tru Face line (full launch expected December 2025) on reversing the 19.8% revenue decline in Mainland China.
- Debt Covenants: Confirm continued compliance with the Credit Agreement leverage ratio (max 2.75:1) and interest coverage ratio (min 3.00:1) following debt repayments.
- India Launch Timeline: Track progress toward the formal India market launch scheduled for H2 2026 and associated capital requirements.